ns19504  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs ns19504
    Ns19504, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ns19504/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ns19504 - by Bioz Stars, 2023-01
    93/100 stars

    Images

    ns19504  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs ns19504
    Ns19504, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ns19504/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ns19504 - by Bioz Stars, 2023-01
    93/100 stars

    Images

    phenytoin  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Alomone Labs phenytoin
    (A, B, C, D) CA1 gamma oscillations evoked by light ramps before and during bath application of <t>phenytoin</t> (A, 40 μM; C, 100 μM). Light ramps were delivered to the CA1 region every 2 min for 40 min of LFP recording sessions. The power spectra in B and D were constructed from the 1.4 s-long LFP traces shown in A and C, respectively. (E) Normalized gamma power before and during bath application of phenytoin (10 min control period followed by 30 min drug period). Note that gamma oscillations were stable in DMSO control ACSF over 40 min, but oscillations were reduced by therapeutic concentrations of phenytoin (i.e., 40 μM and 100 μM). (F) Gamma power during drug application (30-40 min shown in E) and DMSO control period (30-40 min) normalized to gamma power prior to drug exposure (0-10 min). Numbers in the bars indicate numbers of hippocampal slices used for phenytoin or DMSO control experiments. (G) Normalized peak frequencies of gamma oscillations. Note that the peak frequencies were stable in DMSO control ACSF over 40 min, but they were reduced by phenytoin along with a decrease in gamma power. (H) Peak frequencies during drug application (30-40 min shown in G) and DMSO control period (30-40 min) normalized to peak frequencies prior to drug exposure (0-10 min). n.s., not significant; *p < 0.05. The number of slices tested is indicated by “n”.
    Phenytoin, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phenytoin/product/Alomone Labs
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phenytoin - by Bioz Stars, 2023-01
    91/100 stars

    Images

    1) Product Images from "The critical role of persistent sodium current in hippocampal gamma oscillations"

    Article Title: The critical role of persistent sodium current in hippocampal gamma oscillations

    Journal: Neuropharmacology

    doi: 10.1016/j.neuropharm.2019.107787

    (A, B, C, D) CA1 gamma oscillations evoked by light ramps before and during bath application of phenytoin (A, 40 μM; C, 100 μM). Light ramps were delivered to the CA1 region every 2 min for 40 min of LFP recording sessions. The power spectra in B and D were constructed from the 1.4 s-long LFP traces shown in A and C, respectively. (E) Normalized gamma power before and during bath application of phenytoin (10 min control period followed by 30 min drug period). Note that gamma oscillations were stable in DMSO control ACSF over 40 min, but oscillations were reduced by therapeutic concentrations of phenytoin (i.e., 40 μM and 100 μM). (F) Gamma power during drug application (30-40 min shown in E) and DMSO control period (30-40 min) normalized to gamma power prior to drug exposure (0-10 min). Numbers in the bars indicate numbers of hippocampal slices used for phenytoin or DMSO control experiments. (G) Normalized peak frequencies of gamma oscillations. Note that the peak frequencies were stable in DMSO control ACSF over 40 min, but they were reduced by phenytoin along with a decrease in gamma power. (H) Peak frequencies during drug application (30-40 min shown in G) and DMSO control period (30-40 min) normalized to peak frequencies prior to drug exposure (0-10 min). n.s., not significant; *p < 0.05. The number of slices tested is indicated by “n”.
    Figure Legend Snippet: (A, B, C, D) CA1 gamma oscillations evoked by light ramps before and during bath application of phenytoin (A, 40 μM; C, 100 μM). Light ramps were delivered to the CA1 region every 2 min for 40 min of LFP recording sessions. The power spectra in B and D were constructed from the 1.4 s-long LFP traces shown in A and C, respectively. (E) Normalized gamma power before and during bath application of phenytoin (10 min control period followed by 30 min drug period). Note that gamma oscillations were stable in DMSO control ACSF over 40 min, but oscillations were reduced by therapeutic concentrations of phenytoin (i.e., 40 μM and 100 μM). (F) Gamma power during drug application (30-40 min shown in E) and DMSO control period (30-40 min) normalized to gamma power prior to drug exposure (0-10 min). Numbers in the bars indicate numbers of hippocampal slices used for phenytoin or DMSO control experiments. (G) Normalized peak frequencies of gamma oscillations. Note that the peak frequencies were stable in DMSO control ACSF over 40 min, but they were reduced by phenytoin along with a decrease in gamma power. (H) Peak frequencies during drug application (30-40 min shown in G) and DMSO control period (30-40 min) normalized to peak frequencies prior to drug exposure (0-10 min). n.s., not significant; *p < 0.05. The number of slices tested is indicated by “n”.

    Techniques Used: Construct

    (A) A representative reconstruction of an anatomically and neurochemically identified PVBC. The cell was filled with biocytin during whole-cell patch-clamp recordings and was imaged using a Zeiss confocal microscope. Axon arbors were restricted to the pyramidal cell layer of the CA1 region, whereas the dendrites covered most CA1 layers. The recorded PV+ cell showed tdTomato (TOM, thus PV+, right column). Ori., stratum oriens; Pyr., stratum pyramidale; Rad., stratum radiatum. (B) Under control conditions in the presence of synaptic blockers, a neurochemically identified PVBC manifested current responses to voltage ramps (−80 mV to −20 mV, 50 mVs−1) before (black trace) and during (red trace) bath application of TTX (1 μM). The subtracted current was referred to as INaP (green trace). (C, D) In slices pretreated with phenytoin, similar voltage ramps produced negligible INaP (C) or reduced INaP (D) in neurochemically identified PVBCs. (E) Summary data of INaP peak current values. Numbers in bar graph indicate number of PVBCs. (F, G) The TTX-subtracted current responses (INaP) shown in B and C were converted to conductance in F and G, respectively. Note that there was negligible conductance in the PVBC, which was recorded from a hippocampal slice pretreated with phenytoin. *p < 0.05.
    Figure Legend Snippet: (A) A representative reconstruction of an anatomically and neurochemically identified PVBC. The cell was filled with biocytin during whole-cell patch-clamp recordings and was imaged using a Zeiss confocal microscope. Axon arbors were restricted to the pyramidal cell layer of the CA1 region, whereas the dendrites covered most CA1 layers. The recorded PV+ cell showed tdTomato (TOM, thus PV+, right column). Ori., stratum oriens; Pyr., stratum pyramidale; Rad., stratum radiatum. (B) Under control conditions in the presence of synaptic blockers, a neurochemically identified PVBC manifested current responses to voltage ramps (−80 mV to −20 mV, 50 mVs−1) before (black trace) and during (red trace) bath application of TTX (1 μM). The subtracted current was referred to as INaP (green trace). (C, D) In slices pretreated with phenytoin, similar voltage ramps produced negligible INaP (C) or reduced INaP (D) in neurochemically identified PVBCs. (E) Summary data of INaP peak current values. Numbers in bar graph indicate number of PVBCs. (F, G) The TTX-subtracted current responses (INaP) shown in B and C were converted to conductance in F and G, respectively. Note that there was negligible conductance in the PVBC, which was recorded from a hippocampal slice pretreated with phenytoin. *p < 0.05.

    Techniques Used: Patch Clamp, Microscopy, Produced

    (A) Examples of APs from pyramidal cells (1 s-long pulses, +150 pA, 200 pA, or +500 pA from −65 mV). The voltage traces displayed in the left column were from a pyramidal cell in a hippocampal slice pretreated with DMSO control ACSF, whereas the voltage traces shown in the right column were from a pyramidal cell in a hippocampal slice pretreated with phenytoin. (B) Summary of the firing frequency of the recorded pyramidal cells. (C) Summary of the rheobase of the recorded pyramidal cells. Numbers in the bars represents number for pyramidal cells. *p < 0.05. The number of cells tested is indicated by “n”.
    Figure Legend Snippet: (A) Examples of APs from pyramidal cells (1 s-long pulses, +150 pA, 200 pA, or +500 pA from −65 mV). The voltage traces displayed in the left column were from a pyramidal cell in a hippocampal slice pretreated with DMSO control ACSF, whereas the voltage traces shown in the right column were from a pyramidal cell in a hippocampal slice pretreated with phenytoin. (B) Summary of the firing frequency of the recorded pyramidal cells. (C) Summary of the rheobase of the recorded pyramidal cells. Numbers in the bars represents number for pyramidal cells. *p < 0.05. The number of cells tested is indicated by “n”.

    Techniques Used:

    (A) A representative reconstruction of an anatomically identified pyramidal cell that was filled with biocytin during whole-cell patch-clamp recordings (see the methods section for the details). Dendrites of the recorded pyramidal cell covered most CA1 layers. The soma was located in the pyramidal cell layer. Ori., stratum oriens; Pyr., stratum pyramidale; Rad., stratum radiatum; L.M., stratum lacunosum-moleculare. (B) Under control conditions in the presence of synaptic blockers, voltage ramps (−80 mV to −20 mV, 50 mVs−1) were used to evoke INaP in a pyramidal cell. (C) In a hippocampal slice pretreated with phenytoin, similar voltage ramps produced a decrease in INaP of a pyramidal cell. (D) Summary data of INaP peak current values. Numbers in the bars indicate number for pyramidal cells. (E, F) The TTX-subtracted current responses (INaP) shown in B and C were converted to conductance in E and F, respectively. Note that there was lower amplitude conductance in the pyramidal cell, which was recorded from a hippocampal slice pretreated with phenytoin, compared to that in the pyramidal cell, which was recorded from a hippocampal slice pretreated with DMSO control ACSF. *p < 0.05.
    Figure Legend Snippet: (A) A representative reconstruction of an anatomically identified pyramidal cell that was filled with biocytin during whole-cell patch-clamp recordings (see the methods section for the details). Dendrites of the recorded pyramidal cell covered most CA1 layers. The soma was located in the pyramidal cell layer. Ori., stratum oriens; Pyr., stratum pyramidale; Rad., stratum radiatum; L.M., stratum lacunosum-moleculare. (B) Under control conditions in the presence of synaptic blockers, voltage ramps (−80 mV to −20 mV, 50 mVs−1) were used to evoke INaP in a pyramidal cell. (C) In a hippocampal slice pretreated with phenytoin, similar voltage ramps produced a decrease in INaP of a pyramidal cell. (D) Summary data of INaP peak current values. Numbers in the bars indicate number for pyramidal cells. (E, F) The TTX-subtracted current responses (INaP) shown in B and C were converted to conductance in E and F, respectively. Note that there was lower amplitude conductance in the pyramidal cell, which was recorded from a hippocampal slice pretreated with phenytoin, compared to that in the pyramidal cell, which was recorded from a hippocampal slice pretreated with DMSO control ACSF. *p < 0.05.

    Techniques Used: Patch Clamp, Produced

    (A) Examples of APs from PVBCs (1 s –long pulses, +300 pA or +700 pA from −60 mV). The data displayed in the left column were from a PVBC in a hippocampal slice pretreated with DMSO control ACSF, whereas the data shown in the right column were from a PVBC in a hippocampal slice pretreated with phenytoin. (B) Summary of the firing frequency of the recorded PVBCs. (C) Summary of the rheobase of the recorded PVBCs. The numbers in the bars represent numbers for PVBCs. *p < 0.05. The number of cells tested is indicated by “n”.
    Figure Legend Snippet: (A) Examples of APs from PVBCs (1 s –long pulses, +300 pA or +700 pA from −60 mV). The data displayed in the left column were from a PVBC in a hippocampal slice pretreated with DMSO control ACSF, whereas the data shown in the right column were from a PVBC in a hippocampal slice pretreated with phenytoin. (B) Summary of the firing frequency of the recorded PVBCs. (C) Summary of the rheobase of the recorded PVBCs. The numbers in the bars represent numbers for PVBCs. *p < 0.05. The number of cells tested is indicated by “n”.

    Techniques Used:

    No effects of  phenytoin  on AP properties of PVBCs and pyramidal cells in the hippocampus.
    Figure Legend Snippet: No effects of phenytoin on AP properties of PVBCs and pyramidal cells in the hippocampus.

    Techniques Used: T-Test